Inventor · disambiguated record
Xiaobao Yang
Also filed as: YANG XIAOBAO
7 granted patents·13 pending applications·9 citations·filing 2017–2025
75Inventor score
Files withUNIV SHANGHAI TECHNOLOGY10GLUETACS THERAPEUTICS SHANGHAI CO LTD5ICAHN SCHOOL MED MOUNT SINAI5
Top patents by PatentIndex Score
20 records- 0188US11771709B2ALK protein degradation agent and anti-tumor application thereofUNIV SHANGHAI TECHNOLOGY·Filed 2020·Granted Oct 3, 2023·3 cites·44 claims
- 0284US11541051B2Compositions and methods for treating CDK4/6-mediated cancerICAHN SCHOOL MED MOUNT SINAI·Filed 2017·Granted Jan 3, 2023·4 cites·15 claims
- 0377US12226424B2Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediatesUNIV SHANGHAI TECHNOLOGY·Filed 2019·Granted Feb 18, 2025·2 cites·17 claims
- 0470US12274697B2Compositions and methods for treating EZH2-mediated cancerICAHN SCHOOL MED MOUNT SINAI·Filed 2022·Granted Apr 15, 2025·0 cites·12 claims
- 0570US2025064837A1Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediatesUNIV SHANGHAI TECHNOLOGY·Filed 2024·Application pending·0 cites
- 0662US11510920B2Compositions and methods for treating EZH2-mediated cancerICAHN SCHOOL MED MOUNT SINAI·Filed 2020·Granted Nov 29, 2022·0 cites·10 claims
- 0760US2022054488A1Compositions and methods for treating cdk4/6-mediated cancerICAHN SCHOOL MED MOUNT SINAI·Filed 2021·Application pending·0 cites
- 0858US2024425475A1Compound based on quinazoline-substituted glutarimide skeleton and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2024·Application pending·0 cites
- 0957US2025154146A1Protein degraders developed on basis of bcl-2 family protein ligand compounds and use thereofUNIV SHANGHAI TECHNOLOGY·Filed 2023·Application pending·0 cites
- 1056US2019255041A1Compositions and methods for treating ezh2-mediated cancerICAHN SCHOOL MED MOUNT SINAI·Filed 2017·Application pending·0 cites
- 1153US2025320193A1Oxoisoindolinyl substituted piperidinedione derivative and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
- 1253US2025144223A1Protein degradation compound based on nampt target protein and application thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1348US2023096517A1Glutarimide skeleton-based compounds and application thereofUNIV SHANGHAI TECHNOLOGY·Filed 2021·Application pending·0 cites
- 1448US2022016102A1Er protein regulators and use thereofUNIV SHANGHAI TECHNOLOGY·Filed 2019·Application pending·0 cites
- 1548US2025243210A1Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applicationsGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1647US2023203022A1Heterocycle and glutarimide skeleton-based compound and applications thereofUNIV SHANGHAI TECHNOLOGY·Filed 2021·Application pending·0 cites
- 1746US2023303539A1Immunoregulatory compound and antitumor application thereofUNIV SHANGHAI TECHNOLOGY·Filed 2021·Application pending·0 cites
- 1845US11639343B2Compounds targeting and degrading BCR-ABL protein and its antitumor applicationUNIV SHANGHAI TECHNOLOGY·Filed 2020·Granted May 2, 2023·0 cites·29 claims
- 1944US12390532B2ALK protein regulator and anti-tumor application thereofUNIV SHANGHAI TECHNOLOGY·Filed 2020·Granted Aug 19, 2025·0 cites·9 claims
- 2037US2025268906A1Molecular glue compound based on cereblon protein design and use thereofGLUETACS THERAPEUTICS SHANGHAI CO LTD·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiaobao Yang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →